Osteopontin neutralisation abrogates the liver progenitor cell response and fibrogenesis in mice

Gut

Volumn 64, Issue 7, 2015, Pages 1120-1131

  Coombes, J D ^a   Swiderska Syn, M ^b   Dolle L ^c   Reid, D ^d   Eksteen, B ^d   Claridge, L ^e   Briones Orta, M A ^a   Shetty, S ^e   Oo, Y H ^e   Riva, A ^a   Chokshi, S ^a   Papa, S ^a   Mi, Z ^f   Kuo, P C ^f   Williams, R ^a   Canbay, A ^g   Adams, D H ^e   Diehl, A M ^b   Van Grunsven, L A ^c   Choi, S S ^b,h   Syn, W K ^a,e,i   more..

^a INSTITUTE OF HEPATOLOGY   (United Kingdom)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^d UNIVERSITY OF CALGARY   (Canada)

^e UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^f LOYOLA UNIVERSITY CHICAGO   (United States)

^g UNIVERSITY HOSPITAL ESSEN   (Germany)

^h DURHAM VA MEDICAL CENTER   (United States)

ⁱ BARTS HEALTH NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIHYDRO 2,4,6 TRIMETHYL 3,5 PYRIDINEDICARBOXYLIC ACID DIETHYL ESTER; APTAMER; CARBON TETRACHLORIDE; CHOLINE; HYDROXYPROLINE; METHIONINE; NEUTRALIZING ANTIBODY; OSTEOPONTIN; TRANSFORMING GROWTH FACTOR BETA; SOX9 PROTEIN, MOUSE; TRANSCRIPTION FACTOR SOX9;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CELL VIABILITY; CHRONIC LIVER DISEASE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; EPITHELIAL MESENCHYMAL TRANSITION; FIBROGENESIS; HUMAN; HUMAN TISSUE; IN VIVO STUDY; LIVER CELL; LIVER FIBROSIS; LIVER PROGENITOR CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STEM CELL; STEM CELL CULTURE; UPREGULATION; WOUND HEALING; ANIMAL; C57BL MOUSE; DISEASE COURSE; DOWN REGULATION; IMMUNOHISTOCHEMISTRY; LIVER; LIVER CIRRHOSIS; METABOLISM; PATHOLOGY; PHYSIOLOGY;

ANIMALS; DISEASE PROGRESSION; DOWN-REGULATION; IMMUNOHISTOCHEMISTRY; LIVER; LIVER CIRRHOSIS; MICE, INBRED C57BL; OSTEOPONTIN; SOX9 TRANSCRIPTION FACTOR; STEM CELLS; TRANSFORMING GROWTH FACTOR BETA; UP-REGULATION; WOUND HEALING;

EID: 84935026156     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2013-306484     Document Type: Article

References (59)

1. Friedman SL, Sheppard D, Duffield J.S., et al. Therapy for fibrotic diseases: nearing the starting line. Sci Transl Med 2013; 5:167sr161.
2. Schuppan D, Kim YO. Evolving therapies for liver fibrosis. J Clin Invest 2013; 123:1887-901.
3. Schuppan D, Afdhal NH. Liver cirrhosis. Lancet 2008; 371:838-51.
4. Rahimi RS, Rockey DC. End-stage liver disease complications. Curr Opin Gastroenterol 2013; 29:257-63.
5. Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol 2013; 10:686-90.
6. Diehl AM, Chute J. Underlying potential: cellular and molecular determinants of adult liver repair. J Clin Invest 2013; 123:1858-60.
7. Ghosh AK, Quaggin SE, Vaughan DE. Molecular basis of organ fibrosis: potential therapeutic approaches. Exp Biol Med (Maywood) 2013; 238:461-81.
8. Roskams T, Desmet V. Ductular reaction and its diagnostic significance. Semin Diagn Pathol 1998; 15:259-69.
9. Richardson MM, Jonsson JR, Powell E.E., et al. Progressive fibrosis in nonalcoholic steatohepatitis: association with altered regeneration and a ductular reaction. Gastroenterology 2007; 133:80-90.
10. Yang S, Koteish A, Lin H., et al. Oval cells compensate for damage and replicative senescence of mature hepatocytes in mice with fatty liver disease. Hepatology 2004; 39:403-11.
11. Espanol-Suner R, Carpentier R, Van Hul N, et al. Liver progenitor cells yield functional hepatocytes in response to chronic liver injury in mice. Gastroenterology 2012; 143:1564-75 e1567.
12. Dolle L, Best J, Mei J., et al. The quest for liver progenitor cells: a practical point of view. J Hepatol 2010; 52:117-29.
13. Santoni-Rugiu E, Jelnes P, Thorgeirsson S.S., et al. Progenitor cells in liver regeneration: molecular responses controlling their activation and expansion. APMIS 2005; 113:876-902.
14. Petersen BE, Bowen WC, Patrene K.D., et al. Bone marrow as a potential source of hepatic oval cells. Science 1999; 284:1168-70.
15. Oh SH, Witek RP, Bae S.H., et al. Bone marrow-derived hepatic oval cells differentiate into hepatocytes in 2-acetylaminofluorene/partial hepatectomy-induced liver regeneration. Gastroenterology 2007; 132:1077-87.
16. Swiderska-Syn M, Syn WK, Xie G, et al. Myofibroblastic cells function as progenitors to regenerate murine livers after partial hepatectomy. Gut 2013. In press.
17. Arthur MJ, Stanley A, Iredale J.P., et al. Secretion of 72 kDa type IV collagenase/gelatinase by cultured human lipocytes. Analysis of gene expression, protein synthesis and proteinase activity. Biochem J 1992; 287 (Pt 3):701-7.
18. Iredale JP, Goddard S, Murphy G., et al. Tissue inhibitor of metalloproteinase-I and interstitial collagenase expression in autoimmune chronic active hepatitis and activated human hepatic lipocytes. Clin Sci (Lond) 1995; 89:75-81.
19. Wood MJ, Gadd VL, Powell L.W., et al. The ductular reaction in hereditary haemochromatosis: The link between hepatocyte senescence and fibrosis progression. Hepatology 2014; 59:848-57.
20. Holt AP, Salmon M, Buckley C.D., et al. Immune interactions in hepatic fibrosis. Clin Liver Dis 2008; 12:861-82.
21. Carpino G, Renzi A, Onori P., et al. Role of hepatic progenitor cells in nonalcoholic Fatty liver disease development: cellular cross-talks and molecular networks. Int J Mol Sci 2013; 14:20112-30.
22. Omenetti A, Porrello A, Jung Y., et al. Hedgehog signaling regulates epithelial-mesenchymal transition during biliary fibrosis in rodents and humans. J Clin Invest 2008; 118:3331-42.
23. Omenetti A, Syn WK, Jung Y, et al. Repair-related activation of hedgehog signaling promotes cholangiocyte chemokine production. Hepatology 2009; 50:518-27.
24. Syn WK, Jung Y, Omenetti A., et al. Hedgehog-mediated epithelial-to-mesenchymal transition and fibrogenic repair in nonalcoholic fatty liver disease. Gastroenterology 2009; 137:1478-88 e1478.
25. Choi SS, Omenetti A, Witek R.P., et al. Hedgehog pathway activation and epithelial-to-mesenchymal transitions during myofibroblastic transformation of rat hepatic cells in culture and cirrhosis. Am J Physiol Gastrointest Liver Physiol 2009; 297:G1093-1106.
26. Syn WK, Choi SS, Liaskou E, et al. Osteopontin is induced by hedgehog pathway activation and promotes fibrosis progression in nonalcoholic steatohepatitis. Hepatology 2011; 53:106-15.
27. Takahashi F, Takahashi K, Okazaki T., et al. Role of osteopontin in the pathogenesis of bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol 2001; 24:264-71.
28. Liaw L, Birk DE, Ballas C.B., et al. Altered wound healing in mice lacking a functional osteopontin gene (spp1). J Clin Invest 1998; 101:1468-78.
29. Nagao T, Okura T, Irita J., et al. Osteopontin plays a critical role in interstitial fibrosis but not glomerular sclerosis in diabetic nephropathy. Nephron Extra 2012; 2:87-103.
30. Boumans MJ, Houbiers JG, Verschueren P, et al. Safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of the monoclonal antibody ASK8007 blocking osteopontin in patients with rheumatoid arthritis: a randomised, placebo controlled, proof-of-concept study. Ann Rheum Dis 2012; 71:180-5.
31. Nilsson SK, Johnston HM, Whitty G.A., et al. Osteopontin, a key component of the hematopoietic stem cell niche and regulator of primitive hematopoietic progenitor cells. Blood 2005; 106:1232-9.
32. Choi SS, Sicklick JK, Ma Q, et al. Sustained activation of Rac1 in hepatic stellate cells promotes liver injury and fibrosis in mice. Hepatology 2006; 44:1267-77.
33. Fickert P, Stoger U, Fuchsbichler A., et al. A new xenobiotic-induced mouse model of sclerosing cholangitis and biliary fibrosis. Am J Pathol 2007; 171:525-36.
34. Mi Z, Guo H, Russell M.B., et al. RNA aptamer blockade of osteopontin inhibits growth and metastasis of MDA-MB231 breast cancer cells. Mol Ther 2009; 17:153-61.
35. Talbot LJ, Mi Z, Bhattacharya S.D., et al. Pharmacokinetic characterization of an RNA aptamer against osteopontin and demonstration of in vivo efficacy in reversing growth of human breast cancer cells. Surgery 2011; 150:224-30.
36. Kiefer FW, Zeyda M, Gollinger K., et al. Neutralization of osteopontin inhibits obesity-induced inflammation and insulin resistance. Diabetes 2010; 59:935-46.
37. Furuyama K, Kawaguchi Y, Akiyama H., et al. Continuous cell supply from a Sox9-expressing progenitor zone in adult liver, exocrine pancreas and intestine. Nat Genet 2011; 43:34-41.
38. Ishimura N, Bronk SF, Gores GJ. Inducible nitric oxide synthase up-regulates Notch-1 in mouse cholangiocytes: implications for carcinogenesis. Gastroenterology 2005; 128:1354-68.
39. Thenappan A, Li Y, Kitisin K., et al. Role of transforming growth factor beta signaling and expansion of progenitor cells in regenerating liver. Hepatology 2010; 51:1373-82.
40. Michelotti GA, Xie G, Swiderska M., et al. Smoothened is a master regulator of adult liver repair. J Clin Invest 2013; 123:2380-94.
41. Pritchett J, Harvey E, Athwal V., et al. Osteopontin is a novel downstream target of SOX9 with diagnostic implications for progression of liver fibrosis in humans. Hepatology 2012; 56:1108-16.
42. Lee JM, Dedhar S, Kalluri R., et al. The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol 2006; 172:973-81.
43. Tirnitz-Parker JE, Tonkin JN, Knight B, et al. Isolation, culture and immortalisation of hepatic oval cells from adult mice fed a choline-deficient, ethionine-supplemented diet. Int J Biochem Cell Biol 2007; 39:2226-39.
44. Uede T. Osteopontin, intrinsic tissue regulator of intractable inflammatory diseases. Pathol Int 2011; 61:265-80.
45. Deheuninck J, Luo K. Ski and Sno N, potent negative regulators of TGF-beta signaling. Cell Res 2009; 19:47-57.
46. Hayashi H, Abdollah S, Qiu Y., et al. The MAD-related protein Smad7 associates with the TGFbeta receptor and functions as an antagonist of TGFbeta signaling. Cell 1997; 89:1165-73.
47. Chiu CC, Sheu JC, Chen C.H., et al. Global gene expression profiling reveals a key role of CD44 in hepatic oval-cell reaction after 2-AAF/CCl4 injury in rodents. Histochem Cell Biol 2009; 132:479-89.
48. Fedarko NS, Jain A, Karadag A., et al. Three small integrin binding ligand N-linked glycoproteins (SIBLINGs) bind and activate specific matrix metalloproteinases. FASEB J 2004; 18:734-6.
49. Thiery JP, Sleeman JP. Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 2006; 7:131-42.
50. Yang L, Jung Y, Omenetti A., et al. Fate-mapping evidence that hepatic stellate cells are epithelial progenitors in adult mouse livers. Stem Cells 2008; 26:2104-13.
51. Roskams T, Katoonizadeh A, Komuta M. Hepatic progenitor cells: an update. Clin Liver Dis 2010; 14:705-18.
52. Wang KX, Denhardt DT. Osteopontin: role in immune regulation and stress responses. Cytokine Growth Factor Rev 2008; 19:333-45.
53. Pellicoro A, Ramachandran P, Iredale J.P., et al. Liver fibrosis and repair: immune regulation of wound healing in a solid organ. Nat Rev Immunol 2014; 14:181-94.
54. Stroschein SL, Wang W, Zhou S., et al. Negative feedback regulation of TGF-beta signaling by the SnoN oncoprotein. Science 1999; 286:771-4.
55. Fukasawa H, Yamamoto T, Togawa A., et al. Ubiquitin-dependent degradation of SnoN and Ski is increased in renal fibrosis induced by obstructive injury. Kidney Int 2006; 69:1733-40.
56. Lorena D, Darby IA, Gadeau A.P., et al. Osteopontin expression in normal and fibrotic liver. altered liver healing in osteopontin-deficient mice. J Hepatol 2006; 44:383-90.
57. Xanthou G, Alissafi T, Semitekolou M., et al. Osteopontin has a crucial role in allergic airway disease through regulation of dendritic cell subsets. Nat Med 2007; 13:570-8.
58. Weber GF, Cantor H. Differential roles of osteopontin/Eta-1 in early and late lpr disease. Clin Exp Immunol 2001; 126:578-83.
59. Musso G, Paschetta E, Gambino R., et al. Interactions among bone, liver, and adipose tissue predisposing to diabesity and fatty liver. Trends Mol Med 2013; 19:522-35.